A Fenofibrate Diet Prevents Paclitaxel-Induced Peripheral Neuropathy in Mice
Background: Paclitaxel-induced peripheral neuropathy (PIPN) is a major adverse effect of this chemotherapeutic agent that is used in the treatment of a number of solid malignancies. PIPN leads notably to burning pain, cold and mechanical allodynia. PIPN is thought to be a consequence of alterations...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-12-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/13/1/69 |
| _version_ | 1797543226475806720 |
|---|---|
| author | Martial Caillaud Nipa H. Patel Wisam Toma Alyssa White Danielle Thompson Jared Mann Tammy H. Tran Jane L. Roberts Justin L. Poklis John W. Bigbee Xianjun Fang David A. Gewirtz M. Imad Damaj |
| author_facet | Martial Caillaud Nipa H. Patel Wisam Toma Alyssa White Danielle Thompson Jared Mann Tammy H. Tran Jane L. Roberts Justin L. Poklis John W. Bigbee Xianjun Fang David A. Gewirtz M. Imad Damaj |
| author_sort | Martial Caillaud |
| collection | DOAJ |
| description | Background: Paclitaxel-induced peripheral neuropathy (PIPN) is a major adverse effect of this chemotherapeutic agent that is used in the treatment of a number of solid malignancies. PIPN leads notably to burning pain, cold and mechanical allodynia. PIPN is thought to be a consequence of alterations of mitochondrial function, hyperexcitability of neurons, nerve fiber loss, oxidative stress and neuroinflammation in dorsal root ganglia (DRG) and spinal cord (SC). Therefore, reducing neuroinflammation could potentially attenuate neuropathy symptoms. Peroxisome proliferator-activated receptor-α (PPAR-α) nuclear receptors that modulate inflammatory responses can be targeted by non-selective agonists, such as fenofibrate, which is used in the treatment of dyslipidemia. Methods: Our studies tested the efficacy of a fenofibrate diet (0.2% and 0.4%) in preventing the development of PIPN. Paclitaxel (8 mg/kg) was administered via 4 intraperitoneal (i.p.) injections in C57BL/6J mice (both male and female). Mechanical and cold hypersensitivity, wheel running activity, sensory nerve action potential (SNAP), sciatic nerve histology, intra-epidermal fibers, as well as the expression of PPAR-α and neuroinflammation were evaluated in DRG and SC. Results: Fenofibrate in the diet partially prevented the development of mechanical hypersensitivity but completely prevented cold hypersensitivity and the decrease in wheel running activity induced by paclitaxel. The reduction in SNAP amplitude induced by paclitaxel was also prevented by fenofibrate. Our results indicate that suppression of paclitaxel-induced pain by fenofibrate involves the regulation of PPAR-α expression through reduction in neuroinflammation. Finally, co-administration of paclitaxel and the active metabolite of fenofibrate (fenofibric acid) did not interfere with the suppression of tumor cell growth or clonogenicity by paclitaxel in ovarian and breast cancer cell lines. Conclusions: Taken together, our results show the therapeutic potential of fenofibrate in the prevention of PIPN development. |
| first_indexed | 2024-03-10T13:42:38Z |
| format | Article |
| id | doaj.art-64c8c92775b741bfb0cb5b5ebff5570c |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-10T13:42:38Z |
| publishDate | 2020-12-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-64c8c92775b741bfb0cb5b5ebff5570c2023-11-21T02:56:10ZengMDPI AGCancers2072-66942020-12-011316910.3390/cancers13010069A Fenofibrate Diet Prevents Paclitaxel-Induced Peripheral Neuropathy in MiceMartial Caillaud0Nipa H. Patel1Wisam Toma2Alyssa White3Danielle Thompson4Jared Mann5Tammy H. Tran6Jane L. Roberts7Justin L. Poklis8John W. Bigbee9Xianjun Fang10David A. Gewirtz11M. Imad Damaj12Department of Pharmacology and Toxicology and Translational Research Initiative for Pain and Neuropathy, Medical College of Virginia Campus, Virginia Commonwealth University, Richmond, VA 23284, USADepartments of Pharmacology and Toxicology and Medicine and Massey Cancer Center, Virginia Commonwealth University, Massey Cancer Center, Richmond, VA 23284, USADepartment of Pharmacology and Toxicology and Translational Research Initiative for Pain and Neuropathy, Medical College of Virginia Campus, Virginia Commonwealth University, Richmond, VA 23284, USADepartment of Pharmacology and Toxicology and Translational Research Initiative for Pain and Neuropathy, Medical College of Virginia Campus, Virginia Commonwealth University, Richmond, VA 23284, USADepartment of Pharmacology and Toxicology and Translational Research Initiative for Pain and Neuropathy, Medical College of Virginia Campus, Virginia Commonwealth University, Richmond, VA 23284, USADepartment of Pharmacology and Toxicology and Translational Research Initiative for Pain and Neuropathy, Medical College of Virginia Campus, Virginia Commonwealth University, Richmond, VA 23284, USADepartments of Pharmacology and Toxicology and Medicine and Massey Cancer Center, Virginia Commonwealth University, Massey Cancer Center, Richmond, VA 23284, USADepartment of Pharmacology and Toxicology and Translational Research Initiative for Pain and Neuropathy, Medical College of Virginia Campus, Virginia Commonwealth University, Richmond, VA 23284, USADepartment of Pharmacology and Toxicology and Translational Research Initiative for Pain and Neuropathy, Medical College of Virginia Campus, Virginia Commonwealth University, Richmond, VA 23284, USADepartment of Anatomy and Neurobiology, School of Medicine, Virginia Commonwealth University, Richmond, VA 23284, USADepartment of Biochemistry & Molecular Biology, School of Medicine, Virginia Commonwealth University, Richmond, VA 23284, USADepartments of Pharmacology and Toxicology and Medicine and Massey Cancer Center, Virginia Commonwealth University, Massey Cancer Center, Richmond, VA 23284, USADepartment of Pharmacology and Toxicology and Translational Research Initiative for Pain and Neuropathy, Medical College of Virginia Campus, Virginia Commonwealth University, Richmond, VA 23284, USABackground: Paclitaxel-induced peripheral neuropathy (PIPN) is a major adverse effect of this chemotherapeutic agent that is used in the treatment of a number of solid malignancies. PIPN leads notably to burning pain, cold and mechanical allodynia. PIPN is thought to be a consequence of alterations of mitochondrial function, hyperexcitability of neurons, nerve fiber loss, oxidative stress and neuroinflammation in dorsal root ganglia (DRG) and spinal cord (SC). Therefore, reducing neuroinflammation could potentially attenuate neuropathy symptoms. Peroxisome proliferator-activated receptor-α (PPAR-α) nuclear receptors that modulate inflammatory responses can be targeted by non-selective agonists, such as fenofibrate, which is used in the treatment of dyslipidemia. Methods: Our studies tested the efficacy of a fenofibrate diet (0.2% and 0.4%) in preventing the development of PIPN. Paclitaxel (8 mg/kg) was administered via 4 intraperitoneal (i.p.) injections in C57BL/6J mice (both male and female). Mechanical and cold hypersensitivity, wheel running activity, sensory nerve action potential (SNAP), sciatic nerve histology, intra-epidermal fibers, as well as the expression of PPAR-α and neuroinflammation were evaluated in DRG and SC. Results: Fenofibrate in the diet partially prevented the development of mechanical hypersensitivity but completely prevented cold hypersensitivity and the decrease in wheel running activity induced by paclitaxel. The reduction in SNAP amplitude induced by paclitaxel was also prevented by fenofibrate. Our results indicate that suppression of paclitaxel-induced pain by fenofibrate involves the regulation of PPAR-α expression through reduction in neuroinflammation. Finally, co-administration of paclitaxel and the active metabolite of fenofibrate (fenofibric acid) did not interfere with the suppression of tumor cell growth or clonogenicity by paclitaxel in ovarian and breast cancer cell lines. Conclusions: Taken together, our results show the therapeutic potential of fenofibrate in the prevention of PIPN development.https://www.mdpi.com/2072-6694/13/1/69fenofibratePPAR-αpaclitaxelneuropathic painperipheral neuropathy |
| spellingShingle | Martial Caillaud Nipa H. Patel Wisam Toma Alyssa White Danielle Thompson Jared Mann Tammy H. Tran Jane L. Roberts Justin L. Poklis John W. Bigbee Xianjun Fang David A. Gewirtz M. Imad Damaj A Fenofibrate Diet Prevents Paclitaxel-Induced Peripheral Neuropathy in Mice Cancers fenofibrate PPAR-α paclitaxel neuropathic pain peripheral neuropathy |
| title | A Fenofibrate Diet Prevents Paclitaxel-Induced Peripheral Neuropathy in Mice |
| title_full | A Fenofibrate Diet Prevents Paclitaxel-Induced Peripheral Neuropathy in Mice |
| title_fullStr | A Fenofibrate Diet Prevents Paclitaxel-Induced Peripheral Neuropathy in Mice |
| title_full_unstemmed | A Fenofibrate Diet Prevents Paclitaxel-Induced Peripheral Neuropathy in Mice |
| title_short | A Fenofibrate Diet Prevents Paclitaxel-Induced Peripheral Neuropathy in Mice |
| title_sort | fenofibrate diet prevents paclitaxel induced peripheral neuropathy in mice |
| topic | fenofibrate PPAR-α paclitaxel neuropathic pain peripheral neuropathy |
| url | https://www.mdpi.com/2072-6694/13/1/69 |
| work_keys_str_mv | AT martialcaillaud afenofibratedietpreventspaclitaxelinducedperipheralneuropathyinmice AT nipahpatel afenofibratedietpreventspaclitaxelinducedperipheralneuropathyinmice AT wisamtoma afenofibratedietpreventspaclitaxelinducedperipheralneuropathyinmice AT alyssawhite afenofibratedietpreventspaclitaxelinducedperipheralneuropathyinmice AT daniellethompson afenofibratedietpreventspaclitaxelinducedperipheralneuropathyinmice AT jaredmann afenofibratedietpreventspaclitaxelinducedperipheralneuropathyinmice AT tammyhtran afenofibratedietpreventspaclitaxelinducedperipheralneuropathyinmice AT janelroberts afenofibratedietpreventspaclitaxelinducedperipheralneuropathyinmice AT justinlpoklis afenofibratedietpreventspaclitaxelinducedperipheralneuropathyinmice AT johnwbigbee afenofibratedietpreventspaclitaxelinducedperipheralneuropathyinmice AT xianjunfang afenofibratedietpreventspaclitaxelinducedperipheralneuropathyinmice AT davidagewirtz afenofibratedietpreventspaclitaxelinducedperipheralneuropathyinmice AT mimaddamaj afenofibratedietpreventspaclitaxelinducedperipheralneuropathyinmice AT martialcaillaud fenofibratedietpreventspaclitaxelinducedperipheralneuropathyinmice AT nipahpatel fenofibratedietpreventspaclitaxelinducedperipheralneuropathyinmice AT wisamtoma fenofibratedietpreventspaclitaxelinducedperipheralneuropathyinmice AT alyssawhite fenofibratedietpreventspaclitaxelinducedperipheralneuropathyinmice AT daniellethompson fenofibratedietpreventspaclitaxelinducedperipheralneuropathyinmice AT jaredmann fenofibratedietpreventspaclitaxelinducedperipheralneuropathyinmice AT tammyhtran fenofibratedietpreventspaclitaxelinducedperipheralneuropathyinmice AT janelroberts fenofibratedietpreventspaclitaxelinducedperipheralneuropathyinmice AT justinlpoklis fenofibratedietpreventspaclitaxelinducedperipheralneuropathyinmice AT johnwbigbee fenofibratedietpreventspaclitaxelinducedperipheralneuropathyinmice AT xianjunfang fenofibratedietpreventspaclitaxelinducedperipheralneuropathyinmice AT davidagewirtz fenofibratedietpreventspaclitaxelinducedperipheralneuropathyinmice AT mimaddamaj fenofibratedietpreventspaclitaxelinducedperipheralneuropathyinmice |